Find and Pitch Jounalists, Get Your Story Covered

	Profile	Recent Articles on Subject
1	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Avutometinib Plus Defactinib Moves One Step Closer to Approval for Treatment of Ovarian Cancer - 16 days ago CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC - 2 months ago Jazz Pharmaceuticals Submits Biologics License Application for Zanidatamab to Treat Biliary Tract Cancer - 10 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - about 1 year ago
2	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - 20 days ago Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 4 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 5 months ago FDA Grants Fast Track Designation to Potential Treatment for Clear Cell Renal Cell Carcinoma - 7 months ago Dostarlimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit in Endometrial Cancer - 10 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 11 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - 12 months ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago
3	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	MHRA grants approval for bladder cancer drug erdafitinib - 3 months ago
4	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 3 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 7 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago Uterine Cancer Trials Made Waves This Year, Experts Say - about 1 year ago
5	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis - 3 months ago
6	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 4 months ago Embracing a Precision Medicine Approach to KRAS G12C–Mutated Advanced NSCLC With Adagrasib - 10 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 10 months ago
7	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer - 4 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 4 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 5 months ago Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer - 10 months ago Novel Therapy Promising for Radiation-Induced Oral Mucositis - 11 months ago All-Oral Therapy Promising in Higher-Risk MDS, CMML - 12 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - about 1 year ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - over 1 year ago
8	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Gilead sours on the ‘don’t eat me’ business - 12 months ago
9	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	Lutetium Lu 177 Dotatate Reduced Risk of Death By 72% Compared to Comparator in Patients With Advanced GEP-NETs - 12 months ago Phase 3 Results Show First-Line Amivantamab-vmjw Plus Chemotherapy Prolongs Survival In Patients With Advanced or Metastatic NSCLC - about 1 year ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	FDA Issues Complete Response Letter to Astellas for Zolbetuximab BLA for GEJ Adenocarcinoma - about 1 year ago FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment - about 1 year ago ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer - about 1 year ago Zelix Pharmaceuticals Files BLA for PET Imaging Agent for Renal Cell Carcinoma - about 1 year ago FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec - about 1 year ago GSK's Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer - about 1 year ago FDA Approves Keytruda Plus Chemotherapy for Gastric, Gastroesophageal Junction Adenocarcinoma - about 1 year ago FDA Approves Keytruda Plus Chemotherapy for Biliary Tract Cancer - about 1 year ago

Journalists covering gemcitabine